Enliven Therapeutics (NASDAQ:ELVN) Sees Large Volume Increase

Enliven Therapeutics, Inc. (NASDAQ:ELVN) shares saw strong trading volume on Friday . 471,292 shares were traded during mid-day trading, an increase of 114% from the previous session’s volume of 219,724 shares.The stock last traded at $16.88 and had previously closed at $17.67.

Wall Street Analysts Forecast Growth

Separately, Mizuho started coverage on shares of Enliven Therapeutics in a research note on Tuesday, April 9th. They issued a “buy” rating and a $34.00 price objective on the stock.

Enliven Therapeutics Stock Performance

The business has a 50 day moving average price of $17.02 and a 200-day moving average price of $14.33. The company has a market capitalization of $763.94 million, a price-to-earnings ratio of -7.52 and a beta of 1.06.

Enliven Therapeutics (NASDAQ:ELVN) last announced its quarterly earnings data on Thursday, March 14th. The company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.09. As a group, equities analysts predict that Enliven Therapeutics, Inc. will post -2.16 EPS for the current fiscal year.

Insider Buying and Selling

In related news, major shareholder 5Am Partners Vi, Llc sold 500,000 shares of the firm’s stock in a transaction dated Wednesday, January 31st. The shares were sold at an average price of $15.00, for a total value of $7,500,000.00. Following the transaction, the insider now owns 771,983 shares of the company’s stock, valued at approximately $11,579,745. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, CEO Samuel Kintz sold 12,000 shares of the stock in a transaction dated Thursday, January 25th. The shares were sold at an average price of $15.69, for a total value of $188,280.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder 5Am Partners Vi, Llc sold 500,000 shares of the firm’s stock in a transaction dated Wednesday, January 31st. The shares were sold at an average price of $15.00, for a total transaction of $7,500,000.00. Following the transaction, the insider now directly owns 771,983 shares in the company, valued at $11,579,745. The disclosure for this sale can be found here. Insiders have sold a total of 763,661 shares of company stock worth $13,213,762 in the last ninety days. Corporate insiders own 45.80% of the company’s stock.

Hedge Funds Weigh In On Enliven Therapeutics

Several institutional investors have recently modified their holdings of the business. BlackRock Inc. increased its stake in shares of Enliven Therapeutics by 4,476.0% during the 2nd quarter. BlackRock Inc. now owns 1,546,475 shares of the company’s stock worth $31,564,000 after purchasing an additional 1,512,680 shares during the last quarter. State Street Corp raised its position in shares of Enliven Therapeutics by 4,847.5% in the second quarter. State Street Corp now owns 466,251 shares of the company’s stock valued at $9,516,000 after purchasing an additional 456,827 shares during the period. Geode Capital Management LLC raised its position in shares of Enliven Therapeutics by 1,071.1% in the second quarter. Geode Capital Management LLC now owns 414,444 shares of the company’s stock valued at $8,459,000 after purchasing an additional 379,056 shares during the period. Northern Trust Corp purchased a new position in Enliven Therapeutics in the 2nd quarter valued at approximately $3,999,000. Finally, Charles Schwab Investment Management Inc. raised its holdings in Enliven Therapeutics by 150.8% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 156,631 shares of the company’s stock valued at $2,140,000 after acquiring an additional 94,169 shares during the period. 95.08% of the stock is owned by institutional investors.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.